Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation ...

Genetic mutations should be considered when selecting the optimal treatment for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), according to a recent network meta-analysis published in ...

Tumour cells can escape the therapeutic effects of selective JAK2 inhibitors by mutation-independent transactivation of JAK2 by JAK1. Here, we used selective JAK2 inhibition as a model to test the ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Clearance of driver mutations at day 30 after transplantation was associated with a reduced risk of relapse and better ...

P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the ...

A panelist discusses how polycythemia vera (PV) is a rare myeloproliferative neoplasm (MPN) characterized by excessive red blood cell production, primarily affecting older adults with JAK2 mutations, ...

PharmaEssentia is looking to expand the reach of its FDA-approved rare blood cancer treatment Besremi to another rare blood ...

Different Kirsten rat sarcoma virus (KRAS) mutations in pancreatic ductal adenocarcinoma show varying treatment responses, with G12D and G12V mutations linked to worse outcomes compared with wild ...